Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 27, 1070-1104, October 1, 1967]
© 1967 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciaccio, E. I.
Right arrow Articles by Ford, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciaccio, E. I.
Right arrow Articles by Ford, R. T.

Screening Data from Selected in Vitro Enzymatic Systems

II. Compounds Specifically Selected for the Dehydrogenase Inhibition Screens1

Edward I. Ciaccio2,3, George E. Boxer2, Thomas M. Devlin2,4 and Robert T. Ford2

Four dehydrogenase reactions measured in vitro were used to detect compounds of potential use in the chemotherapy of cancer. Inhibitors of lactate dehydrogenase and L-glycerol-3-phosphate dehydrogenase were sought, based on the proposal that inhibition of these enzymes might be more deleterious to malignant than normal tissues. Some compounds were also tested for inhibition of malate and alcohol dehydrogenase, primarily to exclude nonspecific dehydrogenase inhibitors. Results are presented on 259 compounds which were selected for possible structural relationships to substrates or known inhibitors, as well as for diversity of structural types. In an attempt to improve the detection of dehydrogenase inhibitors, 2 modifications of the standard protocol were investigated to select irreversible inhibitors and compounds that might form inhibitory products in vivo. Over 20% of the reported compounds significantly inhibited 1 or more of the dehydrogenases.

1 Supported by contract PH-43-64-883 from the Cancer Chemotherapy National Service Center, National Cancer Institute, USPHS.

2 Merck Sharp & Dohme Research Laboratories, Division of Merck & Co., Inc., Rahway, New Jersey, and West Point, Pennsylvania.

3 Present address: Department of Pharmacology, Hahnemann Medical College, Philadelphia, Pennsylvania.

4 Present address: Department of Biological Chemistry, Hahnemann Medical College, Philadelphia, Pennsylvania.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1967 by the American Association for Cancer Research.